Unleashing the Power of Artificial Intelligence-Driven Drug Discovery in Streptomyces

The rise of antibiotic resistance has created an urgent need for the discovery of new antibiotic compounds. Streptomycin, the first antibiotic isolated from Streptomyces sp., paved the way for discovering other antibiotics for combating bacterial infections. By exploring the genome-based biosynthet...

Full description

Saved in:
Bibliographic Details
Main Authors: Wei-Shan Ang, Jodi Woan-Fei Law, Yatinesh Kumari, Vengadesh Letchumanan, Loh Teng-Hern Tan
Format: Article
Language:English
Published: HH Publisher 2024-11-01
Series:Progress in Microbes and Molecular Biology
Online Access:https://journals.hh-publisher.com/index.php/pmmb/article/view/1081
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832541444065198080
author Wei-Shan Ang
Jodi Woan-Fei Law
Yatinesh Kumari
Vengadesh Letchumanan
Loh Teng-Hern Tan
author_facet Wei-Shan Ang
Jodi Woan-Fei Law
Yatinesh Kumari
Vengadesh Letchumanan
Loh Teng-Hern Tan
author_sort Wei-Shan Ang
collection DOAJ
description The rise of antibiotic resistance has created an urgent need for the discovery of new antibiotic compounds. Streptomycin, the first antibiotic isolated from Streptomyces sp., paved the way for discovering other antibiotics for combating bacterial infections. By exploring the genome-based biosynthetic potential of various Streptomyces species, a vast array of secondary metabolites with potential therapeutic applications can be identified, contributing a transformative impact on the field of medicine. However, conventional screening approaches on novel natural products (NPs) from Streptomyces sp. have entered a bottleneck due to inefficiency. Fortunately, artificial intelligence (AI) and machine learning (ML) models enable rapid exploration and prediction of potential antibiotic compounds, increasing the probability of discovering new antibacterial compounds. AI-driven drug discovery in Streptomyces sp. represents a paradigm shift in the future quest for novel pharmaceutical agents. Various ML models have been developed and applied in different practical applications. Overall, the ML model is trained using input data and generates outcomes based on prediction output. This review discusses the continued potential of Streptomyces sp. as a source of novel NPs, along with the application of ML throughout the NP drug discovery pipeline involving genome mining, biological activities prediction, and optimization compound production in Streptomyces microbial systems. Graphical abstract: The role of machine learning in drug discovery from Streptomyces.
format Article
id doaj-art-dcd7d392ea144637944cfee679264e1c
institution Kabale University
issn 2637-1049
language English
publishDate 2024-11-01
publisher HH Publisher
record_format Article
series Progress in Microbes and Molecular Biology
spelling doaj-art-dcd7d392ea144637944cfee679264e1c2025-02-04T08:39:35ZengHH PublisherProgress in Microbes and Molecular Biology2637-10492024-11-017110.36877/pmmb.a0000453Unleashing the Power of Artificial Intelligence-Driven Drug Discovery in StreptomycesWei-Shan AngJodi Woan-Fei LawYatinesh KumariVengadesh LetchumananLoh Teng-Hern Tan The rise of antibiotic resistance has created an urgent need for the discovery of new antibiotic compounds. Streptomycin, the first antibiotic isolated from Streptomyces sp., paved the way for discovering other antibiotics for combating bacterial infections. By exploring the genome-based biosynthetic potential of various Streptomyces species, a vast array of secondary metabolites with potential therapeutic applications can be identified, contributing a transformative impact on the field of medicine. However, conventional screening approaches on novel natural products (NPs) from Streptomyces sp. have entered a bottleneck due to inefficiency. Fortunately, artificial intelligence (AI) and machine learning (ML) models enable rapid exploration and prediction of potential antibiotic compounds, increasing the probability of discovering new antibacterial compounds. AI-driven drug discovery in Streptomyces sp. represents a paradigm shift in the future quest for novel pharmaceutical agents. Various ML models have been developed and applied in different practical applications. Overall, the ML model is trained using input data and generates outcomes based on prediction output. This review discusses the continued potential of Streptomyces sp. as a source of novel NPs, along with the application of ML throughout the NP drug discovery pipeline involving genome mining, biological activities prediction, and optimization compound production in Streptomyces microbial systems. Graphical abstract: The role of machine learning in drug discovery from Streptomyces. https://journals.hh-publisher.com/index.php/pmmb/article/view/1081
spellingShingle Wei-Shan Ang
Jodi Woan-Fei Law
Yatinesh Kumari
Vengadesh Letchumanan
Loh Teng-Hern Tan
Unleashing the Power of Artificial Intelligence-Driven Drug Discovery in Streptomyces
Progress in Microbes and Molecular Biology
title Unleashing the Power of Artificial Intelligence-Driven Drug Discovery in Streptomyces
title_full Unleashing the Power of Artificial Intelligence-Driven Drug Discovery in Streptomyces
title_fullStr Unleashing the Power of Artificial Intelligence-Driven Drug Discovery in Streptomyces
title_full_unstemmed Unleashing the Power of Artificial Intelligence-Driven Drug Discovery in Streptomyces
title_short Unleashing the Power of Artificial Intelligence-Driven Drug Discovery in Streptomyces
title_sort unleashing the power of artificial intelligence driven drug discovery in streptomyces
url https://journals.hh-publisher.com/index.php/pmmb/article/view/1081
work_keys_str_mv AT weishanang unleashingthepowerofartificialintelligencedrivendrugdiscoveryinstreptomyces
AT jodiwoanfeilaw unleashingthepowerofartificialintelligencedrivendrugdiscoveryinstreptomyces
AT yatineshkumari unleashingthepowerofartificialintelligencedrivendrugdiscoveryinstreptomyces
AT vengadeshletchumanan unleashingthepowerofartificialintelligencedrivendrugdiscoveryinstreptomyces
AT lohtengherntan unleashingthepowerofartificialintelligencedrivendrugdiscoveryinstreptomyces